March 11, 2025 -- The FDA has approved a new treatment for children with generalized myasthenia gravis (gMG), a disease that makes muscles weak and tired quickly. This is the first and only ...

Results of a recent database analysis reveal that patients with juvenile myasthenia gravis—particularly prepubescent girls—might benefit from early thymectomy to cut production of autoreactive ...

Generalised myasthenia gravis (gMG) is a chronic disorder in ... Until now, treatment options for children with gMG have been extremely limited, making this approval particularly significant.

Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially ...

Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with myasthenia gravis. Poster presented at: AMCP 2025; March 31-April 3 ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle ...

The expanded application makes this the first available treatment for myasthenia gravis in children. Soliris is available only through a Risk Evaluation Management Program. The FDA has approved an ...

“This approval represents a major advancement in the treatment of pediatric myasthenia gravis and provides hope ... “The availability of Soliris for children underscores the importance of ...

A myasthenic crisis is a life-threatening complication of myasthenia gravis. It’s when the muscles that you use to breathe get so weak that you can’t get air in and out of your lungs.